Felypressin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Felypressin: From Dental Vasoconstriction to Drug-Induced Osteoporosis
One-Sentence Summary
Felypressin is a synthetic vasopressin analogue (V1a receptor agonist) primarily used as a vasoconstrictor in dental local anaesthetic preparations to prolong anaesthesia and reduce systemic absorption. The TxGNN model predicts it may have therapeutic relevance for Drug-Induced Osteoporosis, ranked 1st among 10 predicted indications with a score of 99.80%. However, no clinical trials and no supporting literature exist for this indication, and the mechanistic rationale is highly speculative — this prediction is currently unsupported by any empirical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vasoconstrictor in dental local anaesthesia |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L5 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available in this Evidence Pack (Data Gap DG002). Based on established pharmacological knowledge, Felypressin (also known as PLV-2) is a synthetic octapeptide analogue of vasopressin that acts primarily as a V1a receptor agonist. It causes smooth muscle contraction and vasoconstriction — particularly in the splanchnic vasculature — with negligible antidiuretic (V2) activity. In dentistry, it is combined with prilocaine to achieve local haemostasis and prolong anaesthetic duration, with systemic exposure kept intentionally minimal.
The proposed link to drug-induced osteoporosis rests on a highly speculative hypothesis: V1a receptors have been reported in low levels on osteoblasts in some preclinical studies, raising the theoretical possibility that vasopressin signalling participates in bone metabolism. However, this relationship remains at the hypothesis stage and has not been translated into any clinical or even robust preclinical models for osteoporosis prevention or treatment.
Critically, Felypressin's pharmacological profile argues strongly against this repurposing direction. Its clinical use is specifically designed to minimise systemic exposure; it is rapidly degraded after injection, has a very short half-life, and any bone-targeted effect would require sustained systemic vasopressin receptor engagement that is neither achievable nor desirable with the current formulation. The mechanistic pathway connecting a transiently acting dental vasoconstrictor to drug-induced bone loss remains without a plausible biological route.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Felypressin is not currently registered or marketed in Singapore. No product authorisations on record.
This drug does not appear in the Singapore Health Sciences Authority (HSA) drug register at the time of this report (data cutoff: 2026-06-21). Any future development or clinical use in Singapore would require full regulatory submission.
Safety Considerations
Safety data for this candidate is currently unavailable (key warnings, contraindications, and drug interaction records all returned no data). Please refer to the product package insert and consult published anaesthesiology and pharmacology references for complete safety information.
Known general safety considerations from the pharmacological literature for vasopressin analogues include caution in patients with cardiovascular disease, hypertension, and conditions requiring splanchnic vasodilation. These considerations are particularly relevant given Felypressin's vasoconstrictor mechanism.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction rests entirely on TxGNN model output (Evidence Level L5) with no clinical trials, no supporting literature, and no plausible mechanistic pathway connecting Felypressin's known pharmacology to drug-induced osteoporosis. The drug's fundamental mode of use — minimal systemic exposure as a transiently acting dental vasoconstrictor — is structurally incompatible with the sustained systemic activity that would be required to influence bone metabolism. Additionally, Felypressin holds no Singapore market authorisation, and critical safety data (package insert warnings, contraindications) are absent from this analysis.
To proceed, the following would be needed:
- Identification of a biologically plausible mechanistic link between V1a receptor agonism and drug-induced osteoporosis (e.g., peer-reviewed preclinical evidence of vasopressin effects on osteoblast or osteoclast activity)
- At least one in vitro or animal model study demonstrating Felypressin or a structurally related vasopressin agonist modulating bone turnover markers
- A feasible drug delivery strategy that could achieve relevant systemic concentrations without the cardiovascular risks inherent to systemic V1a agonism
- Retrieval and review of TFDA/HSA package insert data (Data Gap DG001, severity: Blocking) to assess baseline safety profile
- Formal MOA documentation from DrugBank API (Data Gap DG002) to support mechanistic analysis
Given the structural mismatch between Felypressin's pharmacological identity and the proposed indication, deprioritisation in favour of higher-ranked candidates with stronger mechanistic grounding is recommended.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.